Meeting Overview - The second board meeting of Kefu Medical Technology Co., Ltd. was held on August 7, 2025, with all 7 directors present, including independent director Wen Zhihao attending via communication [1] - The meeting was chaired by Chairman Zhang Min and complied with relevant laws and regulations [1] Board Resolutions - The board approved a proposal to issue overseas listed foreign shares (H shares) and apply for listing on the Hong Kong Stock Exchange to enhance the company's global strategy and brand recognition [1][2] - The proposal received unanimous support with 7 votes in favor, 0 against, and 0 abstentions [2] Listing Details - The H shares will be ordinary shares with a nominal value of RMB 1.00, to be issued in foreign currency [2] - The issuance will occur within 24 months after the shareholders' meeting approval or within an extended period if agreed by shareholders [2] - The issuance method includes public offering in Hong Kong and international placement to qualified institutional investors [3] Issuance Scale and Pricing - The number of H shares issued will not exceed 15% of the total share capital before the issuance, with an option for an additional 15% through an over-allotment option [4] - The pricing will consider existing shareholder interests, investor acceptance, and market conditions, determined by the board and overall coordinators [4][5] Target Investors and Distribution - The issuance will target global investors, including those from Hong Kong, Macau, Taiwan, and other foreign investors [5] - The allocation of shares will depend on the number of valid applications received during the public offering in Hong Kong [6] Fund Utilization - The funds raised will be used for product R&D, global sales network expansion, business development, and working capital [10][11] - The board will have the authority to adjust the use of funds based on regulatory feedback and actual needs [11] Corporate Governance Adjustments - The company plans to amend its articles of association and governance structure to comply with the requirements for H share issuance [14][15] - The board will be authorized to make necessary adjustments to the governance documents post-issuance [15] Independent Director Appointment - The board approved the election of Shen Nan as an independent director, effective upon shareholder meeting approval [18] Committee Adjustments - The composition of various board committees has been adjusted to enhance governance following the appointment of the new independent director [19] Regulatory Compliance - The issuance and listing plan must be submitted for approval to the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2][9]

可孚医疗称，本次发行方式为香港公开发售及国际配售新股。香港公开发售为向香港公众投资者公开发 售，国际配售则向符合投资者资格的国际机构投资者配售。本次发行的H股股数不超过本次发行前公司 总股本的15％（超额配售权行使前），并根据市场情况授权整体协调人行使不超过前述发行的H股股数 15%的超额配售权。本次发行上市的具体细节尚未最终确定。 【大河财立方消息】8月8日，可孚医疗（301087.SZ）发布关于筹划发行H股股票并在香港联合交易所 有限公司上市的提示性公告。 公告称，为加快推进公司全球化战略布局，提升公司海外业务拓展能力，进一步提升公司品牌形象及知 名度，可孚医疗拟发行境外上市外资股（H股）并申请在香港联交所主板挂牌上市。 上市所得的募集资金在扣除相关发行费用后用于以下方面(包括但不限于）：产品研发创新、全球销售 网络扩张、业务拓展及品牌营销、补充营运资金等用途。 实习编辑:金怡杉 | 审核:李震 | 监审:古筝 ...

Group 1 - The China Securities Regulatory Commission (CSRC) has requested Estun (002747.SZ) to provide additional explanations regarding inconsistencies in the identification of its controlling shareholder and the criteria used for this identification [1] - CSRC also requires Estun to clarify the specific situation regarding the pledged shares held by its controlling shareholder and the impact on the company's control and normal business operations, assessing whether it constitutes a situation that prohibits overseas listing [1] - Estun's subsidiary, Nanjing Dingpai Electromechanical Technology Co., Ltd., has faced foreign exchange administrative penalties, and the company must clarify whether fines were paid timely and if corrective actions were completed, as well as the implications for the upcoming listing [1] Group 2 - Estun is recognized as a leading enterprise in the Chinese industrial robot sector, maintaining the highest shipment volume among domestic companies in the industrial robot solutions market for several consecutive years [1] - According to Frost & Sullivan, Estun achieved a historic milestone in Q1 2025 by surpassing foreign brands in domestic industrial robot shipments, becoming the first domestic robot enterprise to lead the Chinese industrial robot solutions market [1]

每经AI快讯，8月8日，普源精电(688337.SH)公告称，公司拟在境外发行股份(H股)并在香港联合交易所 有限公司主板上市，以提高公司综合竞争力，提升国际品牌形象，并利用国际资本市场多元化融资渠 道。该事项尚需提交公司股东大会审议，并需取得相关政府机构、监管机构备案、批准和/或核准。目 前，公司正积极与相关中介机构进行商讨，具体细节尚未最终确定。 ...

Group 1 - The company is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international brand recognition and competitiveness [1][2] - Currently, the company is in discussions with relevant intermediaries regarding the issuance and listing of H-shares, with specific details yet to be determined [1][2] - The issuance and listing of H-shares require approval from the company's board and shareholders, as well as regulatory bodies including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2]

Group 1 - The company, XGIMI Technology, is planning to issue overseas listed shares (H-shares) to enhance its international brand recognition and competitiveness [1] - The company is currently in discussions with relevant intermediaries regarding the issuance and listing of H-shares on the Hong Kong Stock Exchange [1] - Details regarding the issuance and listing of H-shares have not yet been finalized [1]

Group 1 - The core viewpoint of the news is that Jinghe Integrated is planning to list H-shares in Hong Kong to expand its overseas customer base and for strategic investment purposes [1][2] - The company is currently in the planning stage for the H-share issuance, and the specific use of raised funds has not yet been determined [1] - The H-share listing is not expected to significantly impact the company's A-share market [1] Group 2 - Jinghe Integrated reported a revenue of approximately 9.249 billion yuan for 2024, representing a year-on-year growth of 27.69%, attributed to the favorable semiconductor industry conditions and increased sales volume [2] - The net profit attributable to shareholders for 2024 was approximately 533 million yuan, showing a significant year-on-year increase of 151.78%, driven by revenue growth, high capacity utilization, reduced unit sales costs, and improved product gross margins [2] - In the first quarter of 2025, the company achieved a revenue of about 2.568 billion yuan, a year-on-year increase of 15.25%, with a net profit of approximately 135 million yuan, reflecting a year-on-year growth of 70.92% [2] Group 3 - As of August 1, Jinghe Integrated's stock closed at 21.57 yuan per share, with a market capitalization of 43.3 billion yuan [3]

2025年8月2日 公司将依据相关法律法规的规定，根据本次H股上市的后续进展情况及时履行信息披露义务，切实保障 公司及全体股东的合法权益。敬请广大投资者关注后续公告，注意投资风险。 登录新浪财经APP 搜索【信披】查看更多考评等级 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 合肥晶合集成电路股份有限公司董事会 为深化合肥晶合集成电路股份有限公司（以下简称"公司"）国际化战略布局，加快海外业务发展，进一 步提高公司综合竞争力及国际品牌形象，同时充分借助国际资本市场的资源与机制优势，优化资本结 构，拓宽多元融资渠道，公司正在筹划发行境外上市股份（H股）并在香港联合交易所有限公司上市 （以下简称"本次H股上市"）。公司正与相关中介机构就本次H股上市的具体推进工作进行商讨，相关 细节尚未确定。本次H股上市不会导致公司控股股东和实际控制人发生变化。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》 《境内企业境外发行证券和上市管理试行办法》等相关规定，本次H股上市工作尚需提交公 ...

证券代码：688249 证券简称：晶合集成 公告编号：2025-044 为深化合肥晶合集成电路股份有限公司（以下简称"公司"）国际化战略布 局，加快海外业务发展，进一步提高公司综合竞争力及国际品牌形象，同时充分 借助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，公司 正在筹划发行境外上市股份（H 股）并在香港联合交易所有限公司上市（以下简 称"本次 H 股上市"）。公司正与相关中介机构就本次 H 股上市的具体推进工作 进行商讨，相关细节尚未确定。本次 H 股上市不会导致公司控股股东和实际控 制人发生变化。 根据《中华人民共和国公司法》 《中华人民共和国证券法》 合肥晶合集成电路股份有限公司 关于筹划公司在香港联合交易所有限公司上市的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科创板股票上市规则》《境内企业境外发行证券和上市管理试行办法》等相关规 定，本次 H 股上市工作尚需提交公司董事会和股东会审议，并需取得中国证券 监督管理委员会和香港联合交易所有限公司等相关政府机构、监管机构备案、批 ...

证券代码：000975 证券简称：山金国际 公告编号：2025-031 山金国际黄金股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 山金国际黄金股份有限公司（以下简称"公司"）第九届董事会第十四次会 议通知于 2025 年 7 月 25 日以电子邮件及专人递交的方式向全体董事送达，会议 于 2025 年 7 月 28 日上午 9:00 在北京市朝阳区金和东路 20 号院正大中心北塔 实际出席董事 9 人，其中独立董事闫庆悦先生因公务原因未能亲自出席本次会 议，特委托独立董事刘洪渭先生出席并代为行使表决权。公司监事、高级管理人 员列席了会议。 本次会议的召开和表决程序符合《中华人民共和国公司法》 （以下简称"《公 司法》"）和《山金国际黄金股份有限公司章程》（以下简称"《公司章程》"） 等法律、法规的有关规定。经与会董事逐项认真审议，以记名投票表决的方式通 过了如下决议： 一、以9票同意，0票反对，0票弃权，审议通过了关于取消监事会并修订《公 司章程》的议案； 根据《公司法》《关于新〈公司法〉配套制度规则实施相关过渡期安排》《上 市公司章程指引（2 ...